

Diagnosis and Treatment of Bladder Cancer

SANJEEV SHARMA, MD; PANKAJ KSHEERSAGAR, MD; and POONAM SHARMA, MD
Creighton University School of Medicine, Omaha, Nebraska

Bladder cancer is the sixth most prevalent malignancy in the United States. The most common type of bladder cancer is urothelial (transitional cell) carcinoma, and cystoscopy remains the mainstay of diagnosis and surveillance. Fluorescence cystoscopy offers improvement in the detection of flat neoplastic lesions, such as carcinoma in situ. Non-muscle-invasive bladder cancer is typically managed with transurethral resection and perioperative intravesical chemotherapy. Intravesical bacille Calmette-Guérin therapy is preferred over mitomycin for those at high risk of disease progression. For muscle-invasive disease, standard management is radical cystectomy. In these patients, neoadjuvant chemotherapy or postoperative adjuvant chemotherapy should be considered based on pathologic risks, such as positive lymph nodes or pathologic T stage. Multidrug systemic chemotherapy involving cisplatin is commonly used. No major organization recommends screening for bladder cancer. (*Am Fam Physician.* 2009;80(7):717-723. Copyright © 2009 American Academy of Family Physicians.)

► **Patient information:**
A handout on bladder cancer, written by the authors of this article, is available at <http://www.aafp.org/aafp/20091001/717-s1.html>.

■ This article exempts the AAFP 2009 Annual Clinical Focus on management of chronic illness.

Bladder cancer is the second most common genitourinary malignancy.¹ It is the sixth most prevalent malignancy in the United States, accounting for approximately 7 percent of cancers in men and 3 percent of cancers in women.^{1,2} Bladder cancer ranges from mild disease with a low mortality rate to extremely high-grade tumors associated with high mortality. It has a clear correlation with environmental exposures, such as smoking. Accurate staging and grading is important to select optimal treatment. This article briefly reviews the epidemiology, pathology, diagnosis, and treatment of bladder cancer, with emphasis on recent developments.

Epidemiology

Bladder cancer is the fourth most common cancer in men and the eighth most common in women. In 2007, approximately 50,000 men and 17,000 women were diagnosed with bladder cancer, and there were about 14,000 deaths caused by this disease.¹ It is primarily found in older persons, with approximately 80 percent of new cases occurring in persons 60 years or older.² Bladder cancer is about three times more common in men (one in 27) than women (one in 85). It is more prevalent in white persons; however, because of delayed diagnosis, mortality rates are higher in black persons.³

Risk Factors

The best known behavioral risk factor for bladder cancer is cigarette smoking; it accounts for 50 percent of cases in developed countries.⁴ Smokers have a four to seven times greater risk of developing bladder cancer than nonsmokers.^{5,6} In industrialized countries, 5 to 10 percent of bladder cancers are caused by occupational exposures, such as aromatic amines used in the manufacturing of chemical dyes and pharmaceuticals and in gas treatment plants.^{7,8}

Schistosoma haematobium infection, endemic to 50 countries in Africa and the Middle East, is another established risk factor. Seventy percent of *S. haematobium*-related cancers are squamous cell carcinomas, and the remainder are urothelial (transitional cell) carcinomas.⁹ Exposure of the bladder to radiation, often as treatment for other pelvic malignancies, increases the risk of bladder cancer five to 10 years after treatment. These cancers tend to be high grade and locally advanced.⁷ Familial clustering of bladder cancer, especially in relatively young persons, suggests genetic involvement in some cases.^{8,10} Risk factors for bladder cancer are listed in *Table 1*.

Pathology

Approximately 90 percent of epithelial bladder tumors are urothelial carcinomas; the remaining 10 percent are nonurothelial or mesenchymal in origin (*Table 2*).¹¹ The World Health Organization/International

SORT: KEY RECOMMENDATIONS FOR PRACTICE

<i>Clinical recommendation</i>	<i>Evidence rating</i>	<i>References</i>
The U.S. Preventive Services Task Force recommends against routine screening for bladder cancer in adults.	A	24
Patients with symptoms of bladder cancer should be evaluated with cystoscopy and bladder wash cytology.	C	14
Tumor markers should not be used for diagnosis of bladder cancer.	C	23
Fluorescence cystoscopy may be used to enhance the detection of flat neoplastic lesions, such as carcinoma in situ.	C	18
Complete blood count, blood chemistry tests, liver function tests, chest radiography, and CT or magnetic resonance imaging of the abdomen and pelvis should be included in the metastatic workup for invasive bladder cancer.	C	12
All patients with bladder cancer should have an evaluation of the upper urinary tract with intravenous urography, renal ultrasonography, CT urography, or magnetic resonance urography.	C	21, 22
Urine cytology should be used to identify high-grade tumors and monitor patients for persistent or recurrent disease.	C	19, 20

CT = computed tomography.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <http://www.aafp.org/afpsort.xml>.

Society of Urological Pathology classification of urothelial carcinomas was published in 1998 and favors the use of the term “urothelial” over “transitional” to describe epithelial tumors of the bladder.¹¹ The pathologic classification and histologic grading and staging of bladder tumors are shown in *Tables 2¹¹ and 3.¹²*

Clinical Presentation

Painless hematuria is the most common presenting symptom.¹³ Gross blood throughout micturition is suggestive of bladder cancer. The incidence of bladder cancer in a patient with gross hematuria is 20 percent^{14,15} and with microscopic hematuria is 2 percent.¹⁶⁻¹⁸ Symptoms of bladder irritation, such as urinary frequency and urgency, more commonly occur

in patients with bladder carcinoma in situ. Obstructive symptoms may be present if the tumor is located near the urethra or bladder neck. In advanced disease, patients may present with flank pain caused by ureteral obstruction, or with abdominal, pelvic, or bone pain from distant metastases (*Table 4^{1,13}*). Early bladder cancer is not

Table 1. Risk Factors for Bladder Cancer

Behavioral
Cigarette smoking
Chemical exposure
Arsenic in well water
Chronic infection
Bladder calculi, chronic bladder infection, genitourinary tuberculosis, long-term indwelling catheter, schistosomiasis
Iatrogenic
Cyclophosphamide (Cytoxan), pelvic radiation therapy
Occupational
Exposure to aromatic amines (beta-naphthylamine) used in the manufacturing of chemical dyes and pharmaceuticals and in gas treatment plants
Manufacturing (cable, glass, paint, petroleum, tire and rubber, textile); service industry (hairdressers, painters, tar and asphalt workers, truck drivers)

Table 2. Classification of Bladder Cancer

Epithelial neoplasms	Small cell carcinoma
Urothelial (transitional cell) neoplasms (90 percent)	Rare neoplasms
Papilloma	Basaloid squamous cell carcinoma
Flat	Carcinoid tumor
Papillary	Lymphoepithelial carcinoma
Papillary urothelial carcinoma	Melanoma
Low malignant potential	
Low-grade	Nonepithelial (mesenchymal) neoplasms (1 percent)
High-grade	Benign
Invasive urothelial carcinoma	Hemangioma
Lamina propria invasion	Leiomyoma
Muscularis propria (detrusor muscle) invasion	Lipoma
Nonurothelial neoplasms (9 percent)	Neurofibroma
Squamous cell carcinoma	Paraganglioma
Verrucous carcinoma	Malignant
Adenocarcinoma	Angiosarcoma
Clear cell	Leiomyosarcoma
Hepatoid	Malignant fibrous histiocytoma
Nonurachal	Osteosarcoma
Signet ring cell	Rhabdomyosarcoma
Urachal	

Information from reference 11.

Table 3. American Joint Committee on Cancer TNM Staging System for Bladder Cancer

Primary tumor (T)	Regional lymph nodes (N)	Distant metastasis (M)			
TX: Primary tumor cannot be assessed	Regional lymph nodes are those within the true pelvis; all others are distant lymph nodes	MX: Distant metastasis cannot be assessed			
T0: No evidence of primary tumor		M0: No distant metastasis			
Ta: Noninvasive papillary carcinoma		M1: Distant metastasis			
Tis: Carcinoma in situ ("flat tumor")	NX: Regional lymph nodes cannot be assessed	Stage grouping			
T1: Tumor invades subepithelial connective tissue	N0: No regional lymph node metastasis	0a	Ta	N0	M0
T2: Tumor invades muscle	N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension	0is	Tis	N0	M0
pT2a: Tumor invades superficial muscle (inner half)	N2: Metastasis in single lymph node, more than 2 cm but not more than 5 cm in greatest dimension;	I	T1	N0	M0
pT2b: Tumor invades deep muscle (outer half)	or multiple lymph nodes, none more than 5 cm in greatest dimension	II	T2a	N0	M0
T3: Tumor invades perivesical tissue	N3: Metastasis in lymph node more than 5 cm in greatest dimension		T2b	N0	M0
pT3a: Microscopically		III	T3a	N0	M0
pT3b: Macroscopically (extravesical mass)			T3b	N0	M0
T4: Tumor invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall		IV	T4a	N0	M0
T4a: Tumor invades prostate, uterus, vagina			T4b	N0	M0
T4b: Tumor invades pelvic wall, abdominal wall			Any T	N1	M0
			Any T	N2	M0
			Any T	N3	M0
			Any T	Any N	M1

NOTE: Primary tumor assessment includes bimanual examination under anesthesia before and after endoscopic surgery (biopsy or transurethral resection) and histologic verification of the presence or absence of tumor when indicated. Bimanual examination following endoscopic surgery is an indicator of clinical stage. The finding of bladder wall thickening, a mobile mass, or a fixed mass suggest the presence of T3a, T3b, and T4b disease, respectively. Appropriate imaging techniques for lymph node evaluation should be used. When indicated, evaluation for distant metastases includes imaging of the chest, biochemical studies, and isotopic studies to detect common metastatic sites.

Reprinted with permission from *Urinary bladder*. In: Greene FL, Page DL, Fleming ID, et al., eds. *AJCC Cancer Staging Manual*. 6th ed. New York, NY: Springer-Verlag; 2002:335-337.

detectable by physical examination; however, a mass may be palpable in advanced disease. A palpable kidney or pelvic mass may be present in metastatic disease.

Diagnosis

The clinical investigation should begin with a careful history, including any history of cigarette smoking or occupational exposures. Patients with urinary symptoms should have a urinalysis with urine microscopy and a urine culture to rule out infection.

Table 4. Signs and Symptoms of Bladder Cancer

Hematuria (gross or microscopic)
Irritative symptoms
Dysuria, frequency, urge incontinence, urgency
Obstructive symptoms
Decreased force of stream, feeling of incomplete voiding, intermittent stream, straining
Signs and symptoms of metastases or advanced disease
Abdominal, bone, flank, or pelvic pain; anorexia, cachexia, or pallor; lower extremity edema; renal failure; respiratory symptoms (e.g., cough, dyspnea, hemoptysis); suprapubic palpable mass

Information from references 1 and 13.

URINE CYTOLOGY

Urine cytology is a noninvasive test for the diagnosis of bladder cancer. It is used to identify high-grade tumors and monitor patients for persistent or recurrent disease following treatment. Urine cytology has a high specificity (95 to 100 percent), but a low sensitivity (66 to 79 percent) for the detection of bladder cancer.^{19,20} This limits its usefulness for detection of bladder cancer in asymptomatic persons.

CYSTOSCOPY

Cystoscopy, an office procedure usually performed under local anesthesia, remains the mainstay of diagnosis and surveillance. Patients presenting with symptoms of bladder cancer should be evaluated with cystoscopy to determine if a lesion is present. Cystoscopy provides information about the tumor location, appearance, and size. Detection of flat neoplastic lesions, such as carcinoma in situ, can be enhanced by using fluorescence cystoscopy.¹⁸ This involves the use of a photosensitizer, such as 5-aminolevulinic acid or hexaminolevulinic acid, that is instilled intravesically. This induces macroscopic fluorescence of tumor tissue in the bladder. The procedure carries a 5 percent risk of urinary infection.

Bladder wash cytology detects carcinoma in situ in almost all cases, even when the urothelium appears grossly normal, and obviates the need for random

Bladder Cancer

bladder biopsies.^{19,20} Patients with symptoms of bladder cancer should be evaluated with cystoscopy and bladder wash cytology.¹⁴

TRANSURETHRAL RESECTION OF BLADDER TUMOR

Upon detection of a lesion, a bimanual examination under anesthesia and transurethral resection of the tumor is performed. The muscle surrounding the tumor should be sampled to assess the depth of muscle invasion.

EVALUATION OF UPPER URINARY TRACT

Additional workup for all patients with bladder cancer includes evaluation of the upper urinary tract with intravenous urography (IVU), renal ultrasonography, computed tomography (CT) urography, or magnetic resonance urography.^{21,22} Renal ultrasonography alone is insufficient to complete the evaluation of hematuria in a patient with bladder cancer because it cannot delineate details of the urinary collecting system. Traditional IVU has been largely replaced by CT urography because of increased detail and data combined in the CT (e.g., extravesical spread of tumor, lymph node evaluation).

For patients unable to undergo contrast injection (e.g., those with allergy, renal insufficiency), magnetic resonance urography may be used to evaluate the upper urinary tract. These tests are useful for disease staging and excluding other causes of hematuria. Pelvic imaging should be performed before transurethral resection to improve staging accuracy because postoperative inflammation mimics the appearance of tumor infiltration.²¹ Pelvic imaging also may detect synchronous upper tract urothelial cancer, which can occur in 5 percent of patients with bladder cancer.²²

EVALUATION FOR METASTATIC DISEASE

Complete blood count, blood chemistry tests (including alkaline phosphatase tests), liver function tests, chest radiography, and CT or magnetic resonance imaging of the abdomen and pelvis should be included in the metastatic workup for invasive bladder cancer.¹² A bone scan may be performed if the alkaline phosphatase level is elevated or if symptoms suggesting bone metastasis are present.

TUMOR MARKERS

In recent years, there has been an intense debate about the role of urine-based tumor markers in the diagnosis and surveillance of bladder cancer. Newer tumor marker tests

include the bladder tumor antigen (BTA) stat test and BTA Trak test; fluorescence in situ hybridization (FISH) analysis; ImmunoCyt test; nuclear matrix protein 22 (NMP22) test and NMP22 BladderChek test; and telomeric repeat amplification protocol.¹⁶ Tumor marker tests approved by the U.S. Food and Drug Administration, such as NMP tests and FISH analysis for chromosomal changes in cells in urine, have demonstrated a superior sensitivity to urine cytology for low-grade tumors and an equivalent sensitivity for high-grade tumors and carcinoma in situ.²³ No tumor markers have the specificity of traditional urine cytology for detection of bladder cancer; therefore, tumor markers should not be used for diagnosis.²³

Screening

There are no current recommendations for bladder cancer screening. The U.S. Preventive Services Task Force recommends against routine screening for bladder cancer in adults (D recommendation).²⁴ There is no good evidence that the early treatment of this disease improves long-term health outcomes. Urine-based tests, such as urine dipstick to assess for hematuria, urine cytology, and tumor markers (e.g., BTA, NMP22), have been used as screening tools. However, because of the low prevalence of bladder cancer, the positive predictive value of these tests is low.

Treatment

Optimal treatment is multidisciplinary, involving urology, pathology, and oncology (*Tables 5²⁵ and 6²⁵, and Figure 1²⁵*). Close follow-up is essential with bladder cancer (*Table 7^{25,26}*).

Table 5. Treatment of Nonurothelial Bladder Carcinoma

<i>Carcinoma</i>	<i>Treatment</i>
Squamous cell carcinoma	Cystectomy or radiation therapy
Adenocarcinoma	Cystectomy or partial cystectomy Methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (Platinol) ineffective; consider fluorouracil-based therapy
Small cell carcinoma	Neoadjuvant or adjuvant chemotherapy using small cell regimen Local treatment (surgery or radiation therapy)
Mixed histology	Follow urothelial bladder carcinoma guidelines

Information from reference 25.


Table 6. Treatment of Urothelial (Transitional Cell) Bladder Carcinoma

Tumor	Treatment
Low-grade Ta	Transurethral resection without intravesical chemotherapy Some experts suggest a single dose of intravesical chemotherapy (not immunotherapy) within 24 hours of resection to prevent recurrence
High-grade Ta	Repeat transurethral resection (if lymphovascular invasion, incomplete resection, or no muscle in the specimen), consider intravesical BCG (preferred) or mitomycin
Carcinoma in situ/ tumor in situ	Transurethral resection followed by intravesical BCG once a week for six weeks
Low-grade T1	Repeat transurethral resection followed by intravesical BCG (preferred) or mitomycin
High-grade T1	Repeat transurethral resection, followed by intravesical BCG or mitomycin, or cystectomy
T2a or T2b (organ confined)	Radical cystectomy followed by chemotherapy in high-risk patients (e.g., those with nodal involvement, high-grade histology, transmural or vascular invasion, pathologic T3 lesion)
T3a or T3b	Radical cystectomy followed by adjuvant chemotherapy, consider neoadjuvant chemotherapy Two trials have shown survival benefit with neoadjuvant chemotherapy (three cycles of methotrexate, vinblastine, doxorubicin [Adriamycin], and cisplatin [Platinol]) in T2 or T3 disease
T4a, T4b, or metastatic disease	Chemotherapy alone or in combination with radiation therapy, except in high-risk patients (e.g., those with poor performance status, visceral [lung or liver] disease, bone disease, poor cardiac status) Radiation therapy not routinely used in the United States for locally advanced bladder cancer

BCG = bacille Calmette-Guérin.

Information from reference 25.

Management of Bladder Cancer



*—High-risk patients with multiple risk factors, such as cigarette smoking or exposure to chemical dyes.

†—If urine cytology and biopsy are positive, treat per guidelines. If cytology is positive, but biopsy is negative, surveillance is needed.

‡—Metastatic workup would include complete blood count, complete metabolic profile, bone scan (if alkaline phosphatase level is elevated), liver function tests (with CT of the abdomen if elevated), and chest radiography (or chest CT if high risk of metastasis).

Figure 1. Algorithm for the management of bladder cancer. (CT = computed tomography; TURBT = transurethral resection of bladder tumor.)

Information from reference 25.

Table 7. Follow-up for Bladder Cancer

<i>Tumor</i>	<i>Follow-up</i>
Low-grade Ta	Cystoscopy every three months for one year; increase interval as appropriate
T1 and high-grade Ta	Cystoscopy and urine cytology every three months for two years, then every six months for two years, then annually Imaging of the upper tract collecting system every one to two years Urinary tumor markers for urothelial cancer optional
T2 and above (muscle-invasive disease)	Liver function test, creatinine clearance test, electrolyte panel, chest radiography every six to 12 months Imaging of upper urinary tract, abdomen, and pelvis for recurrence every three to six months for two years, and then as clinically indicated If bladder-sparing surgery, urine cytology with or without biopsy every three months for one year, then increase interval If cystectomy, urine cytology every six to 12 months If cystectomy and cutaneous diversion, urethral wash cytology every six to 12 months If cystectomy and continent orthotopic diversion, monitor vitamin B ₁₂ level annually*

*—Vitamin B₁₂ is absorbed exclusively in the terminal ileum; orthotopic diversion is done using ileocecal segments, the resection of which may produce malabsorption of vitamin B₁₂.²⁶

Information from references 25 and 26.

TREATMENT OF NON-MUSCLE-INVASIVE DISEASE

Three stages of bladder cancer (non-muscle-invasive papillary carcinoma [stage Ta], carcinoma in situ [stage Tis], and tumor invading the lamina propria [stage T1]) were previously referred to as superficial bladder cancer, but now are described as non-muscle-invasive bladder cancer. Approximately 70 to 75 percent of bladder cancers present as non-muscle-invasive tumors. These tumors are initially treated by transurethral resection followed by close observation or intravesical chemotherapy or immunotherapy.²⁵

Depth and grade of tumor invasion, completeness of resection, and estimated probability of recurrence are key factors that guide the use of intravesical therapy. Low-grade Ta cancers are treated with resection alone. High-grade Ta and T1 cancers have a higher risk of recurrence and progression to more invasive stages, and therefore may require further resection (repeat transurethral resection of bladder tumor), intravesical bacille Calmette-Guérin (BCG), or mitomycin. Intravesical BCG therapy is preferred over mitomycin for those at high risk of disease progression. Radical cystectomy should be considered for high-risk, non-muscle-invasive bladder cancers, such as recurrent high-grade T1 disease or tumors with micropapillary histology.²⁷ Bladder carcinoma in situ is believed to be a precursor of invasive disease. Transurethral resection followed by intravesical BCG once per week for six weeks is recommended for carcinoma in situ.

MUSCLE-INVASIVE DISEASE

Radical cystectomy with pelvic lymphadenectomy is the standard treatment for muscle-invasive bladder cancer (stage T2 and above).²⁸ Long-term, disease-free survival rates of up to 70 percent can be achieved if pathology

shows no extravesical diseases.²⁸ Radical cystectomy involves cystoprostatectomy in men and cystectomy (usually with hysterectomy) in women, followed by a urinary diversion procedure. Segmental cystectomy may be considered for solitary lesions without carcinoma in situ located in suitable locations. In patients with extensive comorbid disease, bladder preservation strategies (transurethral resection with or without chemotherapy) are sometimes used instead of cystectomy to limit treatment-associated morbidity.

Neoadjuvant and adjuvant chemotherapy has been explored in patients with muscle-invasive disease and is best reserved for high-risk patients (e.g., those with nodal involvement, high-grade histology, transmural or vascular invasion, pathologic T3 lesion). Combination gemcitabine (Gemzar) and cisplatin (Platinol) is the standard treatment for most patients because of its lower toxicity. Combination methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (MVAC) has comparable effectiveness to gemcitabine/cisplatin; however, toxicity limits its use.²⁹ Chemotherapy is not used for nonurothelial cancers, such as squamous cell carcinoma or adenocarcinoma, which are primarily treated with cystectomy.

METASTATIC DISEASE

Patients with metastatic disease are treated with chemotherapy. The specific chemotherapy regimen depends on existence of medical comorbidities, such as cardiac and renal dysfunction. A commonly used combination is cisplatin and gemcitabine or a multidrug cisplatin-based regimen, such as MVAC. Carboplatin-based regimens are used in patients with insufficient renal reserve. If muscle invasion has occurred, radical cystectomy with pelvic lymphadenectomy remains the treatment of

choice. Lifestyle modifications, including smoking cessation, are an integral part of treatment. Upon diagnosis, patients require continuous surveillance (*Table 7^{25,26}*) because most recurrences can be successfully treated if detected early.

The authors thank Paulos Yohannes, MD, for critical review of the manuscript, and Eugene Barone, MD, and Thomas Guck, PhD, for help with grammar and syntax.

The Authors

SANJEEV SHARMA, MD, MBBS, is an assistant professor in the Department of Family Medicine at Creighton University School of Medicine in Omaha, Neb.

PANKAJ KSHEERSAGAR, MD, MBBS, is chief resident in the Department of Family Medicine at Creighton University School of Medicine.

POONAM SHARMA, MD, MBBS, is an assistant professor in the Department of Pathology at Creighton University School of Medicine.

Address correspondence to Sanjeev Sharma, MD, MBBS, Creighton Family Health Care Center, 7909 N. 30th St., Omaha, NE 68112 (e-mail: ssharma@creighton.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

- American Cancer Society. Cancer facts & figures 2007. Atlanta, Ga.: American Cancer Society; 2007. <http://www.cancer.org/downloads/STT/CAFF2007PWsecured.pdf>. Accessed August 19, 2009.
- Ries LA, Melbert D, Krapcho M, et al., eds. SEER cancer statistics review, 1975-2004. Bethesda, Md.: National Cancer Institute; 2006. http://seer.cancer.gov/csr/1975_2004/. Accessed August 19, 2009.
- Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published correction appears in *CA Cancer J Clin*. 2005;55(4):259]. *CA Cancer J Clin*. 2005;55(1):10-30.
- Jankovic S, Radosavljevic V. Risk factors for bladder cancer. *Tumori*. 2007;93(1):4-12.
- Morrison AS. Advances in the etiology of urothelial cancer. *Urol Clin North Am*. 1984;11(4):557-566.
- Burch JD, Rohan TE, Howe GR, et al. Risk of bladder cancer by source and type of tobacco exposure: a case-control study. *Int J Cancer*. 1989;44(4):622-628.
- Quilty PM, Kerr GR. Bladder cancer following low or high dose pelvic irradiation. *Clin Radiol*. 1987;38(6):583-585.
- Lin J, Spitz MR, Dinney CP, Etzel CJ, Grossman HB, Wu X. Bladder cancer risk as modified by family history and smoking. *Cancer*. 2006;107(4):705-711.
- Lucas SB. Squamous cell carcinoma of the bladder and schistosomiasis. *East Afr Med J*. 1982;59(5):345-351.
- Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, Kiemeny LA. Familial aggregation of urothelial cell carcinoma. *Int J Cancer*. 2002;98(2):274-278.
- Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. *Am J Surg Pathol*. 1998;22(12):1435-1448.
- Urinary bladder. In: Greene FL, Page DL, Fleming ID, et al., eds. *AJCC Cancer Staging Manual*. 6th ed. New York, NY: Springer-Verlag; 2002:335-340.
- Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. *Cancer Pract*. 2002;10(6):311-322.
- Mohr DN, Offord KP, Owen RA, Melton LJ III. Asymptomatic microhematuria and urologic disease. A population-based study. *JAMA*. 1986;256(2):224-229.
- Golin AL, Howard RS. Asymptomatic microscopic hematuria. *J Urol*. 1980;124(3):389-391.
- Koss LG, Deitch D, Ramanathan R, Sherman AB. Diagnostic value of cytology of voided urine. *Acta Cytol*. 1985;29(5):810-816.
- Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. *N Engl J Med*. 2003;348(23):2330-2338.
- Zaak D, Karl A, Knüchel R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. *BJU Int*. 2005;96(2):217-222.
- Soloway MS, Murphy WM, Johnson DE, Farrow GM, Paulson DF, Garnick MB. Initial evaluation and response criteria for patients with superficial bladder cancer. Report of a workshop. *Br J Urol*. 1990;66(4):380-385.
- Murphy WM, Soloway MS, Jukkola AF, Crabtree WN, Ford KS. Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. *Cancer*. 1984;53(7):1555-1565.
- Turney BW, Willatt JM, Nixon D, Crew JP, Cowan NC. Computed tomography urography for diagnosing bladder cancer. *BJU Int*. 2006;98(2):345-348.
- Smith H, Weaver D, Barjenbruch O, Weinstein S, Ross G Jr. Routine excretory urography in follow-up of superficial transitional cell carcinoma of bladder. *Urology*. 1989;34(4):193-196.
- Gutiérrez Baños JL, Rebollo Rodrigo MH, Antolín Juárez FM, Martín García B. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. *Urol Int*. 2001;66(4):185-190.
- U.S. Preventive Services Task Force. Screening for bladder cancer in adults. Rockville, Md.: Agency for Healthcare Research and Quality; June 2004. <http://www.ahrq.gov/clinic/uspstf/uspblad.htm>. Accessed August 19, 2009.
- National Comprehensive Cancer Network. Bladder cancer including upper tract tumors and urothelial carcinoma of the prostate. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [subscription required]. Accessed August 19, 2009.
- Ganesan T, Khadra MH, Wallis J, Neal DE. Vitamin B12 malabsorption following bladder reconstruction or diversion with bowel segments. *ANZ J Surg*. 2002;72(7):479-482.
- Barocas DA, Clark PE. Bladder cancer. *Curr Opin Oncol*. 2008;20(3):307-314.
- Huang GJ, Stein JP. Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. *Curr Opin Urol*. 2007;17(5):369-375.
- Roberts JT, von der Maase H, Sengelov L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. *Ann Oncol*. 2006;17(suppl 5):v118-v122.